



Tarus Therapeutics Strengthens its Board of Directors with Appointment of Paolo Pucci

NEW YORK, NY, USA – December 2, 2020

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointment of Paolo Pucci as a new Board Director.

Mr. Pucci most recently served as the Chief Executive Officer of ArQule, Inc., a targeted therapeutics oncology company that was acquired by Merck for \$2.7bn in January 2020. Prior to ArQule, Mr. Pucci served in various leadership positions at Bayer AG from 2001 to 2008, including President of the Oncology & Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer, Mr. Pucci served in multiple roles at Eli Lilly and Company from 1991 to 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci earned an MS in economics and accounting from Università degli Studi di Napoli Federico II and an MBA from the University of Chicago. Mr. Pucci has previously served on the Boards of several successful biotech companies including Algeta ASA, until it was acquired by Bayer AG, and Dyax, Inc., until it was acquired by Shire, Plc. He currently serves as a board member of West Pharmaceuticals Services, Inc., Merus N.V., Replimmune, Inc., and Trillium Therapeutics, Inc.

“I look forward to seeing the full potential of Tarus’ comprehensive pipeline of best-in-class adenosine receptor antagonists and contributing my experience in oncology drug development over the coming years,” said Mr. Pucci. “It is an exciting time to be developing next generation immuno-oncology agents, and Tarus is well positioned in the field.”

“We are delighted to welcome Paolo to our Board of Directors at this exciting and significant phase for Tarus Therapeutics as we prepare to move into clinical studies,” added Dr. Sushant Kumar, Board Member and Chief Executive Officer of Tarus Therapeutics, Inc. “Paolo brings with him a wealth of experience and we look forward to his valuable contributions as we advance the Company’s adenosine receptor antagonist programs for cancer immunotherapy and other select non-oncology indications.”

About Tarus Therapeutics Inc.

Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.



TARUS THERAPEUTICS

Contact:

Tarus Therapeutics, Inc.

Sushant Kumar, PhD

President & CEO

info@tarustx.com